According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company’s product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. “
Several other research firms have also recently commented on APTX. JPMorgan Chase & Co. cut shares of Aptinyx from a neutral rating to an underweight rating in a report on Tuesday, August 13th. BMO Capital Markets cut their price objective on shares of Aptinyx from $15.00 to $13.00 and set an outperform rating on the stock in a research report on Wednesday. Cowen reaffirmed a buy rating on shares of Aptinyx in a research report on Thursday. Wedbush initiated coverage on shares of Aptinyx in a research report on Thursday, September 12th. They set an outperform rating and a $7.00 price objective on the stock. Finally, ValuEngine raised shares of Aptinyx from a hold rating to a buy rating in a research report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $11.11.
Aptinyx stock traded up $0.07 during trading hours on Friday, hitting $3.33. 86,400 shares of the company traded hands, compared to its average volume of 75,003. The firm has a market cap of $114.11 million, a P/E ratio of -1.26 and a beta of 0.01. The firm’s 50-day simple moving average is $3.24 and its two-hundred day simple moving average is $3.45. Aptinyx has a 1-year low of $2.61 and a 1-year high of $26.74.
Aptinyx (NASDAQ:APTX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.44) EPS for the quarter, hitting the consensus estimate of ($0.44). The business had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $0.91 million. Aptinyx had a negative net margin of 1,523.09% and a negative return on equity of 42.34%. Analysts anticipate that Aptinyx will post -1.89 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of APTX. SG Americas Securities LLC bought a new position in Aptinyx during the second quarter valued at approximately $49,000. Gabelli Funds LLC raised its position in Aptinyx by 45.9% during the second quarter. Gabelli Funds LLC now owns 15,901 shares of the company’s stock valued at $53,000 after acquiring an additional 5,000 shares in the last quarter. Acadian Asset Management LLC bought a new position in Aptinyx during the second quarter valued at approximately $195,000. Jacobs Levy Equity Management Inc. bought a new position in Aptinyx during the second quarter valued at approximately $54,000. Finally, Weiss Asset Management LP bought a new position in shares of Aptinyx in the second quarter valued at approximately $65,000. 51.81% of the stock is currently owned by hedge funds and other institutional investors.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Featured Article: Penny Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.